Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
28/07/2025 07:32
July 28 (Reuters) - Alteogen Inc 196170.KQ: ALTEOGEN RECEIVES POSITIVE CHMP OPINION FOR AFLIBERCEPT BIOSIMILAR, 'EYLUXVI® (ALT-L9)' Source text: ID:nPn9640nCa Further company coverage: 196170.KQ ((Reuters.Briefs@thomsonreuters.com))
Recent news on Alteogen
See all newsBrief: Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics
Brief: Alteogen Signs Licensing Deal With Biogen International For Alt-B4
Brief: Alteogen 2025 Operating Profit 115 Billion Won, Up 275% From Year Earlier
Brief: Alteogen Signs $285 Million Contract With Gsk Unit
Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'